Ameritas Investment Partners’s Kalaris Therapeutics KLRS Stock Holding History

Ameritas Investment Partners’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-105	Closed	-$1.82K	–	3250
2024 Q1	$1.82K	Hold	105	–	–	﹤0.01%	3033
2023 Q4	$1.64K	Hold	105	–	–	﹤0.01%	3066
2023 Q3	$5.18K	Hold	105	–	–	﹤0.01%	2983
2023 Q2	$8.19K	Hold	105	–	–	﹤0.01%	2959
2023 Q1	$9.49K	Hold	105	–	–	﹤0.01%	2743
2022 Q4	$12.4K	Hold	105	–	–	﹤0.01%	2750
2022 Q3	$18K	Hold	105	–	–	﹤0.01%	2579
2022 Q2	$9K	Hold	105	–	–	﹤0.01%	2871
2022 Q1	$16K	Hold	105	–	–	﹤0.01%	2655
2021 Q4	$31K	Hold	105	–	–	﹤0.01%	2426
2021 Q3	$60K	Hold	105	–	–	﹤0.01%	2039
2021 Q2	$48K	Hold	105	–	–	﹤0.01%	2214
2021 Q1	$56K	Buy	105 +39	+59%	+$32.8K	﹤0.01%	2022
2020 Q4	$59K	Hold	66	–	–	﹤0.01%	1888
2020 Q3	$42K	Buy	+66	New	+$45.1K	﹤0.01%	1946

Other funds holding KLRS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameritas Investment Partners's KLRS Position: Q2 2024 in Review

Ameritas Investment Partners sold out of Kalaris Therapeutics (KLRS) in Q2 2024, closing a stake of 105 shares — an estimated $1.82K sold.

Ameritas Investment Partners first reported a position in KLRS in Q3 2020 and held it in 15 quarters. The position peaked at $60K in Q3 2021. 71 funds tracked by Wall St. Rank hold KLRS as of Q2 2024.

Ameritas Investment Partners reported no remaining Kalaris Therapeutics position as of Q2 2024 after selling out during the quarter.
Ameritas Investment Partners sold 105 Kalaris Therapeutics shares in Q2 2024, an estimated $1.82K.
Ameritas Investment Partners first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 15 quarters.
Ameritas Investment Partners's Kalaris Therapeutics position peaked at $60K in Q3 2021.
71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2024.

Based on Ameritas Investment Partners's 13F filing for Q2 2024, filed 13 Aug 2024.